Lee Ju Hee, Min Dong Suk, Lee Chan Woo, Song Kwang Ho, Kim Yeong Shik, Kim Hyun Pyo
College of Pharmacy, Kangwon National University, Chuncheon, Republic of Korea.
College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
J Ginseng Res. 2018 Oct;42(4):476-484. doi: 10.1016/j.jgr.2017.05.005. Epub 2017 Jun 8.
Korean Red Ginseng (steamed and dried white ginseng, Meyer) is well known for enhancing vital energy and immune capacity and for inhibiting cancer cell growth. Some clinical studies also demonstrated a therapeutic potential of ginseng extract for treating lung inflammatory disorders. This study was conducted to establish the therapeutic potential of ginseng saponins on the lung inflammatory response.
From Korean Red Ginseng, 11 ginsenosides (Rb1, Rb2, Rb3, Rc, Rd, Re, Rf, Rg1, Rg2, Rg3, and Rh2) were isolated. Their inhibitory potential and action mechanism were evaluated using a mouse model of lung inflammation, acute lung injury induced by intranasal lipopolysaccharide administration. Their anti-inflammatory activities were also examined in lung epithelial cell line (A549) and alveolar macrophage (MH-S).
All ginsenosides orally administered at 20 mg/kg showed 11.5-51.6% reduction of total cell numbers in bronchoalveolar lavage fluid (BALF). Among the ginsenosides, Rc, Re, Rg1, and Rh2 exhibited significant inhibitory action by reducing total cell numbers in the BALF by 34.1-51.6% ( = 5). Particularly, Re showed strong and comparable inhibitory potency with that of dexamethasone, as judged by the number of infiltrated cells and histological observations. Re treatment clearly inhibited the activation of mitogen-activated protein kinases, nuclear factor-κB, and the c-Fos component in the lung tissue ( = 3).
Certain ginsenosides inhibit lung inflammatory responses by interrupting these signaling molecules and they are potential therapeutics for inflammatory lung diseases.
高丽参（蒸制和干燥的白参，迈耶）以增强活力和免疫能力以及抑制癌细胞生长而闻名。一些临床研究还证明人参提取物在治疗肺部炎症性疾病方面具有治疗潜力。本研究旨在确定人参皂苷对肺部炎症反应的治疗潜力。
从高丽参中分离出11种人参皂苷（Rb1、Rb2、Rb3、Rc、Rd、Re、Rf、Rg1、Rg2、Rg3和Rh2）。使用鼻内给予脂多糖诱导的肺部炎症小鼠模型、急性肺损伤模型评估它们的抑制潜力和作用机制。还在肺上皮细胞系（A549）和肺泡巨噬细胞（MH-S）中检测了它们的抗炎活性。
所有以20mg/kg口服给药的人参皂苷均使支气管肺泡灌洗液（BALF）中的总细胞数减少了11.5-51.6%。在这些人参皂苷中，Rc、Re、Rg1和Rh2通过使BALF中的总细胞数减少34.1-51.6%（P=5）表现出显著的抑制作用。特别是，根据浸润细胞数量和组织学观察判断，Re显示出与地塞米松相当的强大抑制效力。Re处理明显抑制了肺组织中丝裂原活化蛋白激酶、核因子-κB和c-Fos成分的激活（P=3）。
某些人参皂苷通过中断这些信号分子来抑制肺部炎症反应，它们是炎症性肺病的潜在治疗药物。
